Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

Breast cancer is one the most common cause of cancer death in women worldwide. We report here the first phase II study investigating a virus genetically engineered for tumor-selective replication in patients with breast cancer. Ten patients were treated with a combination of low-dose oral cyclophosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cousin, Sophie, Toulmonde, Maud, Kind, Michèle, Guegan, Jean-Philippe, Bessede, Alban, Cantarel, Coralie, Bellera, Carine, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724410/
https://www.ncbi.nlm.nih.gov/pubmed/36474303
http://dx.doi.org/10.1186/s40164-022-00338-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724410/
https://www.ncbi.nlm.nih.gov/pubmed/36474303
http://dx.doi.org/10.1186/s40164-022-00338-2

Ejemplares similares